WO2012007783A8 - Kits and methods for detecting the ability to induce an immunogenic cancer cell death in a subject - Google Patents

Kits and methods for detecting the ability to induce an immunogenic cancer cell death in a subject Download PDF

Info

Publication number
WO2012007783A8
WO2012007783A8 PCT/IB2010/002034 IB2010002034W WO2012007783A8 WO 2012007783 A8 WO2012007783 A8 WO 2012007783A8 IB 2010002034 W IB2010002034 W IB 2010002034W WO 2012007783 A8 WO2012007783 A8 WO 2012007783A8
Authority
WO
WIPO (PCT)
Prior art keywords
subject
cancer
treatment
induce
methods
Prior art date
Application number
PCT/IB2010/002034
Other languages
French (fr)
Other versions
WO2012007783A1 (en
Inventor
Laurence Zitvogel
Guido Kroemer
Nicolas Delahaye
Original Assignee
Institut Gustave Roussy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Gustave Roussy filed Critical Institut Gustave Roussy
Priority to PCT/IB2010/002034 priority Critical patent/WO2012007783A1/en
Priority to PCT/EP2011/055134 priority patent/WO2011131472A1/en
Priority to US13/642,221 priority patent/US8828944B2/en
Priority to EP20110713731 priority patent/EP2561088A1/en
Priority to EP14165240.4A priority patent/EP2806034B1/en
Publication of WO2012007783A1 publication Critical patent/WO2012007783A1/en
Priority to US13/772,944 priority patent/US8865653B2/en
Publication of WO2012007783A8 publication Critical patent/WO2012007783A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Abstract

The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility to a cancer treatment of a subject having a tumour. These methods comprise a step of determining the ability of the treatment, of the subject and/or of the tumour to induce an anticancer immune response, the inability of at least one of the treatment, the subject and the tumor to induce an anticancer immune response being indicative of a resistance of the subject to the therapeutic treatment of cancer. Inventors in particular identify genes specific of a human subject or of cancerous cells which can be used to predict or assess the sensitivity of a subject to a treatment of cancer. The invention also relates to particular compounds capable of activating or enhancing the immune system of a particular subject, when the subject is exposed to a therapeutic treatment of cancer or before such an exposition. It further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The present invention in addition provides kits, methods for selecting a compound of interest, as well as pharmaceutical compositions and uses thereof.
PCT/IB2010/002034 2010-04-22 2010-07-13 Kits and methods for detecting the ability to induce an immunogenic cancer cell death in a subject WO2012007783A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PCT/IB2010/002034 WO2012007783A1 (en) 2010-07-13 2010-07-13 Kits and methods for detecting the ability to induce an immunogenic cancer cell death in a subject
PCT/EP2011/055134 WO2011131472A1 (en) 2010-04-22 2011-04-01 Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
US13/642,221 US8828944B2 (en) 2010-04-22 2011-04-01 Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
EP20110713731 EP2561088A1 (en) 2010-04-22 2011-04-01 Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
EP14165240.4A EP2806034B1 (en) 2010-04-22 2011-04-01 Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
US13/772,944 US8865653B2 (en) 2010-04-22 2013-02-21 Method of treatment for immunogenic treatment resistant cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2010/002034 WO2012007783A1 (en) 2010-07-13 2010-07-13 Kits and methods for detecting the ability to induce an immunogenic cancer cell death in a subject

Publications (2)

Publication Number Publication Date
WO2012007783A1 WO2012007783A1 (en) 2012-01-19
WO2012007783A8 true WO2012007783A8 (en) 2013-07-25

Family

ID=43479616

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/002034 WO2012007783A1 (en) 2010-04-22 2010-07-13 Kits and methods for detecting the ability to induce an immunogenic cancer cell death in a subject

Country Status (1)

Country Link
WO (1) WO2012007783A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975087B2 (en) 2010-11-24 2015-03-10 Inanovate, Inc. Longitudinal assay
WO2014018801A1 (en) * 2012-07-25 2014-01-30 The Texas A&M University System Diagnosis and treatment of cancer using differentially expressed starvation markers
WO2014150853A1 (en) * 2013-03-15 2014-09-25 Inanovate, Inc. Analyte measurement using longitudinal assay
WO2014150860A1 (en) * 2013-03-15 2014-09-25 Inanovate, Inc. Analysis methods of time-resolved assay data
WO2014150869A1 (en) * 2013-03-15 2014-09-25 Inanovate, Inc. Cartridge device for processing time-resolved assays
EP3140421B8 (en) 2014-05-09 2020-05-06 Eurofins LifeCodexx GmbH Detection of dna that originates from a specific cell-type and related methods
EP2942400A1 (en) 2014-05-09 2015-11-11 Lifecodexx AG Multiplex detection of DNA that originates from a specific cell-type
KR102569813B1 (en) 2014-11-21 2023-08-24 브리스톨-마이어스 스큅 컴퍼니 Antibodies against cd73 and uses thereof
EP3789399A1 (en) 2014-11-21 2021-03-10 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
HUE050491T2 (en) * 2015-11-10 2020-12-28 Eurofins Lifecodexx Gmbh Detection of foetal chromosomal aneuploidies using dna regions that are differentially methylated between the foetus and the pregnant female
CN107312837A (en) * 2017-06-26 2017-11-03 广州医科大学 A kind of primer sets of detection rs2066853 loci gene types and its detection kit and application

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US90917A (en) 1869-06-08 Improved mode of forming the connections of gas-purifiers
AU2002360452A1 (en) * 2001-11-28 2003-06-10 Dnaprint Genomics, Inc. Single nucleotide polymorphisms and combinations thereof predictive for paclitaxel responsiveness
KR20070099564A (en) * 2004-12-17 2007-10-09 베리덱스, 엘엘씨 Methods for assessing patients with acute myeloid leukemia
CN101194027B (en) * 2005-06-08 2012-10-24 日立化成研究中心公司 Method for predicting immune response to neoplastic disease based on mRNA expression profile in neoplastic cells and stimulated leukocytes
WO2008028968A2 (en) 2006-09-08 2008-03-13 Institut Gustave Roussy Compounds regulating calreticulin, kdel receptor and/or erp-57 cell surface exposure and uses thereof to evaluate the efficiency of a cancer treatment
US20090131268A1 (en) * 2007-09-14 2009-05-21 Affymetrix, Inc. Methods for Genotyping Polymorphisms
US20090307179A1 (en) * 2008-03-19 2009-12-10 Brandon Colby Genetic analysis
GB0805312D0 (en) * 2008-03-20 2008-04-30 Medical Res Council Modulation of the immune response

Also Published As

Publication number Publication date
WO2012007783A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
WO2012007783A8 (en) Kits and methods for detecting the ability to induce an immunogenic cancer cell death in a subject
WO2012174256A3 (en) Dna methylation profiles in cancer
ZA201604468B (en) Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
NZ704295A (en) Compositions and methods for the treatment of infections and tumors
BR112012018132A2 (en) "Tumor stem cell markers and their use".
WO2014004990A3 (en) Methods for determining drug efficacy using cereblon-associated proteins
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
WO2012097313A3 (en) Therapeutic antibodies against ror-1 protein and methods for use of same
BR112012020373A8 (en) isolated antibody, cell, isolated nucleic acid, method of identification, cell proliferation inhibition, therapeutic treatment, determination of the presence of a tat419 protein, diagnosis of the presence of cancer and distribution of cytotoxic agent
WO2010081001A3 (en) Recurrent gene fusions in cancer
WO2014127917A8 (en) Combination of vaccination and inhibition of the pd-1 pathway
WO2013089882A3 (en) Recurrent gene fusions in breast cancer
EP2373794A4 (en) Nectin-4 for target genes of cancer therapy and diagnosis
WO2011034906A3 (en) Recurrent gene fusions in prostate cancer
MX2015001716A (en) Niclosamide and its derivatives for use in the treatment of solid tumors.
MX365418B (en) Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies.
WO2014026768A8 (en) Colorectal cancer markers
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
WO2012158780A3 (en) Lung cancer signature
WO2012028679A3 (en) Prognostic and/or predictive biomarkers and biological applications thereof
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
WO2009103741A3 (en) Use of fsh receptor ligands for diagnosis and therapy of cancer
WO2012143481A3 (en) Prostate cancer markers
WO2010045573A3 (en) Tumor vaccine

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE